Atrial fibrillation (AF) is associated with a five-fold increase in the risk of thromboembolic
events (stroke/systemic embolism). When initiated in individuals at risk of a thromboembolic …

Oral anticoagulant therapy is the mainstay of stroke prevention in patients with atrial
fibrillation; it is highly effective at reducing stroke risk, but its use can be limited by increased …

Atrial fibrillation (AF) is an increasing public health issue, especially owing to an
accompanying five-fold increased risk of stroke. Anticoagulants are the cornerstone of …

Atrial fibrillation affects millions of people worldwide and significantly increases the risk of
ischemic stroke. In this month's Viewpoint, Alan Go examines the use of anticoagulant …

Introduction Effective stroke prevention with oral anticoagulation (OAC) reduces the risk of
stroke and death among patients with atrial fibrillation (AF). For most patients with AF …

Atrial fibrillation (AF) is the most common sustained arrhythmia of the Western world. The
increased ischemic stroke risk of the AF patient is one of the most important clinical issues to …

Atrial fibrillation (AF) is a major and widely recognized risk factor for cardioembolic stroke.
Prophylactic therapy for the prevention of stroke in patients with AF is often achieved through …

Cerebrovascular accidents related to atrial fibrillation (AF) are potentially preventable with
anticoagulation. Until recently, warfarin was the only proven anticoagulant to be effective in …

New anticoagulants add to the therapeutic options for patients with atrial fibrillation, and offer
a number of advantages over warfarin, for both the clinician and patient, including a …

The most common arrhythmia, atrial fibrillation (AF), increases with age and is associated
with a 5-fold increased risk of stroke. Although lifelong oral anticoagulation (OAC) is strongly …